NHS Approves New GIST Cancer Drug After 3 Treatments Fail

Patients with advanced gastrointestinal stromal tumors in England just gained a lifeline they desperately needed.

On March 31, 2026, the National Institute for Health and Care Excellence approved ripretinib for NHS use, giving patients a fourth treatment option when the first three stop working. For people like Cathy Hampshire, who's tried every available therapy over five years, this approval means hope where there was once only uncertainty.

Gastrointestinal stromal tumors are rare cancers that affect about 6,000 Americans yearly, typically appearing in the stomach or small intestine. When standard treatments stop working, patients often have just weeks to live with no other options.

Ripretinib works differently than earlier drugs by blocking multiple cancer growth signals, including the resistant mutations that develop after other treatments fail. Clinical trials showed it extends survival while causing fewer side effects than existing therapies.

Hampshire, Vice-Chair of GIST Cancer UK, has been on her third and final approved treatment for two and a half years. She described living with constant fear at every scan, bracing for the moment doctors tell her the drug has stopped working.

Richard Davidson, Chief Executive of Sarcoma UK, called the approval excellent news for patients with extremely limited options. His organization's 2020 survey found that 95% of GIST patients reported their diagnosis negatively affected their mental health and emotional wellbeing.

Both Sarcoma UK and GIST Cancer UK actively supported the approval process, submitting patient experiences and advocating throughout the review. Their involvement helped demonstrate not just the physical benefits but the crucial psychological support of knowing another treatment exists.

The Ripple Effect

This approval matters beyond the physical benefits of extended survival. Knowing a fourth treatment option exists provides psychological relief for patients currently on earlier therapies, reducing the anxiety of facing a dead end.

The decision also highlights how patient advocacy groups can shape healthcare policy by sharing real experiences. Hampshire and others contributed their stories to help regulators understand what living with limited options truly means.

For families watching loved ones exhaust treatment options, this approval transforms conversations from "there's nothing left" to "we have another path forward." That shift alone can restore hope during the most difficult moments.

A fourth treatment option means patients can focus on living fully today instead of constantly fearing tomorrow.